com_NN
Discovery_NN
We_FPP1
continue_VPRT
to_TO
increase_VB
our_FPP1
efficiency_NN
in_PIN
identifying_VBG
high_JJ
quality_NOMZ
compounds_NN
with_PIN
the_DT
potential_JJ
to_TO
become_VB
new_JJ
medicines_NN
._.
Jan_NN
Lundberg_NN
,_,
Executive_NN
Vice-President_NN
,_,
Discovery_NN
Research_NN
Every_QUAN
new_JJ
medicine_NN
is_VPRT [BEMA]
the_DT
result_NN
of_PIN
an_DT
Medical_JJ
research_NN
is_VPRT [BEMA]
more_EMPH
exciting_PRED
than_PIN
intensive_JJ
and_CC
focused_VBD
research_NN
process_NN
._.
ever_RB
as_IN
new_JJ
technology_NN
is_VPRT [PASS]
applied_VBN
to_PIN
We_FPP1
examine_VPRT
closely_RB
all_QUAN
the_DT
possibilities_NOMZ
to_TO
understanding_VBG [PRIV]
what_WP [WHCL]
causes_VPRT
disease_NN
find_VB [PRIV]
the_DT
most_EMPH
effective_JJ
treatment_NOMZ
for_PIN
the_DT
and_ANDC
how_RB
it_PIT
may_POMD
be_VB [PASS]
prevented_VBN
or_CC
treated_VBN
._.
Thousands_NN
of_PIN
Our_FPP1
effort_NN
in_PIN
recent_JJ
years_NN
to_TO
improve_VB
the_DT
compounds_NN
are_VPRT [PASS]
investigated_VBN
,_,
only_DWNT
a_DT
small_JJ
links_NN
between_PIN
basic_JJ
science_NN
and_CC
clinical_JJ
number_NN
succeed_VB
._.
It_PIT
is_VPRT [BEMA]
a_DT
complex_JJ
,_,
expensive_JJ
medicine_NN
has_VPRT [PEAS]
helped_VBN
us_FPP1
to_TO
gain_VB
a_DT
better_JJ
and_PHC
risky_JJ
process_NN
taking_VBG [WZPRES]
over_RP
10_CD
years_NN
understanding_GER
of_PIN
human_JJ
diseases_NN
and_CC
and_CC
typically_RB
costing_VBG
around_PLACE
$_$
1_CD
billion_CD
,_,
how_RB
future_JJ
medicines_NN
will_PRMD
work_VB
against_PIN
but_CC
it_PIT
is_VPRT [BEMA]
an_DT
exciting_JJ
and_PHC
rewarding_JJ
one_CD
._.
We_FPP1
also_RB
continue_VPRT
to_TO
introduce_VB
earlier_TIME
in_PIN
the_DT
process_NN
more_EMPH
stringent_JJ
,_,
We_FPP1
have_VPRT
a_DT
world_NN
leading_VBG [WZPRES]
R&D_NN
organization_NOMZ
,_,
and_ANDC
where_RB
possible_JJ
high_JJ
throughput_NN
,_,
with_PIN
over_IN
11,900_CD
people_NN
at_PIN
11_CD
major_JJ
centres_NN
testing_GER
of_PIN
drug_NN
safety_NN
and_ANDC
how_RB
a_DT
medicine_NN
in_PIN
seven_CD
countries_NN
comprising_VBG [WZPRES]
six_CD
joint_JJ
gets_VPRT
distributed_VBN
around_PLACE
,_,
and_ANDC
out_PIN [STPR]
,_,
of_PIN
the_DT
discovery_NN
and_PHC
development_NOMZ
facilities_NOMZ
in_PIN
the_DT
human_JJ
body_NN
._.
This_DEMP
helps_VPRT
us_FPP1
to_TO
eliminate_VB
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
:_:
a_DT
further_JJ
four_CD
earlier_TIME
the_DT
candidate_NN
drugs_NN
CDs_NN
that_TOBJ
sites_NN
in_PIN
the_DT
US_FPP1
,_,
Canada_NN
,_,
India_NN
and_PHC
France_NN
are_VPRT [BEMA]
less_RB
likely_PRED
to_TO
succeed_VB
._.
During_PIN
2004_CD
,_,
which_WDT [SERE]
focus_VPRT
only_DWNT
on_PIN
discovery_NN
,_,
and_ANDC
a_DT
18_CD
CDs_NN
were_VBD [PASS]
selected_VBN
for_PIN
development_NOMZ
._.
facility_NOMZ
in_PIN
Japan_NN
for_PIN
development_NOMZ
only_DWNT
._.
These_DEMO
resources_NN
are_VPRT [BYPA]
complemented_VBN
by_PIN
Partnerships_NN
clinical_JJ
development_NOMZ
at_PIN
43_CD
sites_NN
around_PLACE
the_DT
In_PIN
todays_NN
world_NN
of_PIN
rapid_JJ
scientific_JJ
and_CC
world_NN
._.
We_FPP1
spend_VPRT
around_PLACE
$_$
15_CD
million_CD
each_QUAN
technological_JJ
advance_NN
,_,
no_SYNE
company_NN
working_VBG [WZPRES]
day_NN
in_PIN
the_DT
search_NN
for_PIN
new_JJ
medicines_NN
,_,
can_POMD
rely_VB
exclusively_RB
on_PIN
its_PIT
own_JJ
discovery_NN
and_CC
we_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
delivering_VBG
new_JJ
,_,
and_ANDC
development_NOMZ
._.
We_FPP1
work_VPRT
with_PIN
leading_VBG
medically_RB
important_JJ
and_CC
commercially_RB
academic_JJ
centres_NN
to_TO
broaden_VB
the_DT
successful_JJ
products_NN
to_TO
market_VB
every_QUAN
year_NN
._.
base_NN
for_PIN
disease_NN
research_NN
and_CC
during_PIN
2004_CD
,_,
we_FPP1
entered_VBD
into_PIN
more_EMPH
than_PIN
250_CD
Discovery_NN
new_JJ
collaborations_NOMZ
,_,
including_VBG [PRESP]
a_DT
major_JJ
Our_FPP1
Discovery_NN
scientists_NN
use_VPRT
leading_VBG
edge_NN
strategic_JJ
alliance_NN
with_PIN
Cambridge_NN
science_NN
and_PHC
technologies_NN
to_TO
identify_VB
new_JJ
Antibody_NN
Technology_NN
to_TO
discover_VB [PRIV]
and_PHC
compounds_VPRT
with_PIN
high_JJ
potential_NN
as_IN
new_JJ
develop_VB
human_JJ
antibody_NN
therapeutics_NN
in_PIN
medicines_NN
,_,
working_VBG
across_PLACE
boundaries_NN
inflammatory_JJ
disorders_NN
._.
This_DEMP
complements_VPRT
to_TO
exchange_VB
ideas_NN
,_,
to_TO
share_VB
best_JJ
practice_NN
a_DT
similar_JJ
alliance_NN
in_PIN
cancer_NN
research_NN
with_PIN
and_CC
to_TO
make_VB
the_DT
most_EMPH
of_PIN
the_DT
efficiencies_NN
Abgenix_NN
Inc._NN
announced_VBD [PUBV]
in_PIN
2003_CD
._.
that_DEMO
global_JJ
working_VBG
offers_NN
._.
